Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer (Q42465729)

1 November 2017

Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer (English)

1 reference

1 November 2017

0 references

1 reference

Guido Bellezza

15

0 references

Stefania Damiani

object named as

Stefania Damiani

10

0 references

author name string

Federico Cappuzzo

1

1 reference

1 November 2017

Elisabetta Magrini

2

1 reference

1 November 2017

Giovanni Luca Ceresoli

3

1 reference

1 November 2017

Stefania Bartolini

4

1 reference

1 November 2017

Elisa Rossi

5

1 reference

1 November 2017

Vienna Ludovini

6

1 reference

1 November 2017

Vanesa Gregorc

7

1 reference

1 November 2017

Claudia Ligorio

8

1 reference

1 November 2017

Alessandra Cancellieri

9

1 reference

1 November 2017

Anna Spreafico

11

1 reference

1 November 2017

Carlo Terenzio Paties

12

1 reference

1 November 2017

Laura Lombardo

13

1 reference

1 November 2017

Cesare Calandri

14

1 reference

1 November 2017

Maurizio Tonato

16

1 reference

1 November 2017

Lucio Crinò

17

1 reference

1 November 2017

language of work or name

English

0 references

publication date

1 August 2004

1 reference

Journal of the National Cancer Institute

1 November 2017

1 reference

1 November 2017

96

1 reference

1 November 2017

15

1 reference

1 November 2017

1133-1141

1 reference

PI3K: downstream AKTion blocks apoptosis

1 November 2017

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH217

Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH217

Regulation of cell death protease caspase-9 by phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH217

Akt signaling: linking membrane events to life and death decisions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH217

Akt-dependent and -independent survival signaling pathways utilized by insulin-like growth factor I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH217

Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH217

Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH217

Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH217

AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH217

Non-small cell lung cancers frequently express phosphorylated Akt; an immunohistochemical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH217

Tyrosine kinase inhibition: an approach to drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH217

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH217

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH217

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH217

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH217

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH217

Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH217

Mitogenic activation, phosphorylation, and nuclear translocation of protein kinase Bbeta

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH217

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH217

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH217

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH217

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH217

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH217

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH217

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJH217

1 reference

1 November 2017

1 reference